Steve Soper,
Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine,
The University of Kansas
Prof. Soper (since 2016) is a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas. At KUMC, Prof. Soper holds an adjunct appointment in the Cancer Biology Department and is a member of the KU Cancer Center. He also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor.
As a result of his efforts, Prof. Soper has secured extramural funding totaling >$125M, has published over 245 peer-reviewed manuscripts (h index = 70; >17,000 citations); 31 book chapters and 71 peer-reviewed conference proceeding papers, and is the author of 12 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of liquid biopsy markers. Soper recently founded a second company, Sunflower Genomics, which is seeking to market a new DNA/RNA single-molecule sequencing platform. His list of awards includes Ralph Adams Award in Bioanalytical Chemistry, Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 50 PhDs and 7 MS degrees to students under his mentorship. He currently heads a group of 15 researchers.
His major discoveries include: (1) Technology for the detection of liquid biopsy markers that can manage a variety of diseases using a simple blood test (test has been demonstrated in multiple myeloma, pediatric acute lymphoblastic leukemia, acute myeloid leukemia, pancreatic, breast, colorectal, prostate, and ovarian cancers); (2) new hardware and assay for the point-of-care diagnosis of acute ischemic stroke; (3) single-molecule DNA and RNA sequencing nanotechnology; and (4) currently working on a home-test for COVID-19 infections (handheld instrument and the associated assay.
Extracellular Vesicles (EVs) and Cell Free DNA (cfDNA) as Blood-based Biomarkers: Plastic-based Microfluidics for their Enrichment and Analysis
Tuesday, 5 June 2018 at 10:45
Add to Calendar ▼2018-06-05 10:45:002018-06-05 11:45:00Europe/LondonExtracellular Vesicles (EVs) and Cell Free DNA (cfDNA) as Blood-based Biomarkers: Plastic-based Microfluidics for their Enrichment and AnalysisOrgan-on-a-Chip, Tissue-on-a-Chip Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
While there are a plethora of different blood-based markers, EVs are
generating significant interests due to their relatively high abundance
(~1013 particles per mL of blood) and the information they
carry. EVs contain a diverse array of nucleic acids, such as mRNA,
lncRNA, and miRNA that can be used for disease management. In addition
to EVs, cfDNA also are biomarkers that can be used to help manage
different disease states using the mutations they possess that can have
high diagnostic value. In spite of the relatively high abundance of
cfDNA in diseased patients (~160 ng/mL), the extraction and enrichment
of cfDNA has been inefficient, even by commercial kits, due to the low
abundance of the tumor bearing DNA fragments (<0.01%) and the short
nature of these fragments, especially cancer-related cfDNA (as small as
50 bp). In this presentation, we will discuss the design, fabrication
and analytical figures-of-merit of a microfluidic device that can serve
the dual purpose for the affinity-based selection of EVs and the solid
phase extraction of cfDNA directly from plasma using the same device.
The microfluidic is made from a plastic that can be injection molded to
produce high quality devices at low cost. For EVs, the device is made
cyclic olefin copolymer (COC) is UV/O3 activated to allow for the
efficient immobilization of affinity agents to the surface of the
device. In the case of cfDNA, the device is made from COC as well, but
is only UV/O3 activated (i.e., no affinity agents used). Information
will be provided as to the ability to molecularly profile the cargo
contained within the affinity-selected EVs, in particular mRNA
expression profiling. We will also discuss the use of this microfluidic
to isolate with high recovery cfDNA from plasma samples with size
selection capabilities. The isolated cfDNA could be queried for
mutations using an allele-specific ligation detection reaction at a
mutant to wild-type ratio <0.1%.
Add to Calendar ▼2018-06-05 00:00:002018-06-06 00:00:00Europe/LondonOrgan-on-a-Chip, Tissue-on-a-Chip Europe 2018Organ-on-a-Chip, Tissue-on-a-Chip Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-06-05 10:45:002018-06-05 11:45:00Europe/LondonExtracellular Vesicles (EVs) and Cell Free DNA (cfDNA) as Blood-based Biomarkers: Plastic-based Microfluidics for their Enrichment and AnalysisOrgan-on-a-Chip, Tissue-on-a-Chip Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
